← All trials
NCT03535272
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2018
- Primary completion
- May 1, 2019
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 488
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centers for Disease Control and Prevention (CDC)Lead sponsor
- Centers for Disease Control and Prevention (CDC)Reponsible party - principal investigator
- Centers for Disease Control and Prevention (CDC)Collaborator
- Procter and GambleCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.